The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...

Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

The pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualized exacerbation rate (AER) at 52 weeks ...

COPD can be treated with inhalers. Inhalers can contain one, two, or three different medications. These medications include long-acting bronchodilators (LABA and LAMA), which open (dilate) the airways ...

A long-term real-world study of older adults with COPD shows that initiation of tiotropium is linked to a minimal increase in dementia risk, which is unlikely to outweigh its clinical benefits.

Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to a new study published in Chronic Obstructive Pulmonary Diseases ...

Background: Single triple-therapy inhalers containing inhaled corticosteroids, long-acting beta 2-agonists, and long-acting muscarinic antagonists (ICS-LAMA-LABA) confer benefit to certain patient ...

SINGAPORE, May 14, 2025 /PRNewswire/ -- The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive ...

BREZTRI should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition BREZTRI is NOT a rescue inhaler.

Adults with COPD who used inhaled corticosteroids for more than 24 months faced higher risks for diabetes, osteoporosis, pneumonia, cataracts and fractures than those with less than 4 months&rsquo ...